FDA Accepts Mineralys' NDA For Lorundrostat In Hypertension; Reports Phase 2 Explore-OSA Trial Data

FDA accepted Mineralys Therapeutics' NDA for lorundrostat for adult hypertension in combination with other antihypertensive drugs — a key regulatory milestone that advances the candidate toward potential approval and commercialization. Acceptance initiates the FDA review process and is likely a modest positive catalyst for MLYS equity, potentially moving the stock by low-single-digit percentages if review proceeds favorably.

Analysis

FDA accepted Mineralys Therapeutics' NDA for lorundrostat for adult hypertension in combination with other antihypertensive drugs — a key regulatory milestone that advances the candidate toward potential approval and commercialization. Acceptance initiates the FDA review process and is likely a modest positive catalyst for MLYS equity, potentially moving the stock by low-single-digit percentages if review proceeds favorably.